Devonian Announces the Grant of Stock Options
Devonian Health Group Inc. (TSXv: GSD), a clinical stage botanical pharmaceutical , has announced the grant of stock options approved by its Board of Directors. The company, which focuses on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, has issued a total of 3,298,611 options to its officers.
The options come with an exercise price of $0.16 and are valid for a period of 10 years from the date of grant. Notably, these options are exercisable immediately upon grant, providing immediate potential value to the recipients. This move may be seen as a strategy to align the interests of the company's officers with those of the shareholders.
Devonian Health Group Inc. (TSXv: GSD), un'azienda farmaceutica botanica in fase clinica, ha annunciato l'assegnazione di opzioni su azioni approvate dal suo Consiglio di Amministrazione. L'azienda, che si concentra sullo sviluppo di un portafoglio unico di prodotti farmaceutici botanici e cosmeceutici, ha emesso un totale di 3.298.611 opzioni ai suoi dirigenti.
Le opzioni presentano un prezzo di esercizio di $0,16 e sono valide per un periodo di 10 anni dalla data di concessione. È importante notare che queste opzioni sono esercitabili immediatamente alla concessione, offrendo un valore potenziale immediato ai destinatari. Questa mossa potrebbe essere interpretata come una strategia per allineare gli interessi dei dirigenti dell'azienda con quelli degli azionisti.
Devonian Health Group Inc. (TSXv: GSD), una farmacéutica botánica en fase clínica, ha anunciado la concesión de opciones sobre acciones aprobadas por su Junta Directiva. La empresa, que se centra en el desarrollo de un portafolio único de productos farmacéuticos botánicos y cosmeceúticos, ha emitido un total de 3.298.611 opciones a sus funcionarios.
Las opciones vienen con un precio de ejercicio de $0,16 y son válidas por un período de 10 años a partir de la fecha de concesión. Notablemente, estas opciones son ejercitables de inmediato tras la concesión, proporcionando un valor potencial inmediato a los receptores. Este movimiento puede interpretarse como una estrategia para alinear los intereses de los funcionarios de la empresa con los de los accionistas.
Devonian Health Group Inc. (TSXv: GSD), 임상 단계의 식물 의약품 기업이 이사회에서 승인된 주식 옵션 부여를 발표했습니다. 독특한 식물 의약품 및 코스메슈티컬 제품 포트폴리오 개발에 중점을 두고 있는 이 회사는 3,298,611개의 옵션을 임원들에게 발행했습니다.
이 옵션은 행사 가격이 $0.16이며 부여일로부터 10년 동안 유효합니다. 특히, 이 옵션은 부여 즉시 행사 가능하여 수령자에게 즉각적인 잠재 가치를 제공합니다. 이 조치는 회사 임원들의 이해관계를 주주들과 일치시키려는 전략으로 볼 수 있습니다.
Devonian Health Group Inc. (TSXv: GSD), une société pharmaceutique botanique en phase clinique, a annoncé l'octroi d'options d'achat d'actions approuvées par son conseil d'administration. L'entreprise, qui se concentre sur le développement d'un portefeuille unique de produits pharmaceutiques botaniques et cosméceutiques, a émis un total de 3.298.611 options à ses dirigeants.
Les options ont un prix d'exercice de 0,16 $ et sont valables pour une période de 10 ans à compter de la date d'octroi. Il est à noter que ces options sont immédiatement exerçables dès l'octroi, offrant une valeur potentielle immédiate aux bénéficiaires. Ce mouvement peut être perçu comme une stratégie pour aligner les intérêts des dirigeants de l'entreprise avec ceux des actionnaires.
Devonian Health Group Inc. (TSXv: GSD), ein klinisches Unternehmen der botanischen Pharmazeutika, hat die Genehmigung für die Gewährung von Aktienoptionen durch seinen Vorstand bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung eines einzigartigen Portfolios von botanischen pharmazeutischen und kosmetischen Produkten konzentriert, hat insgesamt 3.298.611 Optionen an seine Führungskräfte ausgegeben.
Die Optionen haben einen Ausübungspreis von $0,16 und sind für einen Zeitraum von 10 Jahren ab dem Datum der Gewährung gültig. Bemerkenswert ist, dass diese Optionen sofort nach Gewährung ausgeübt werden können, was den Empfängern sofortigen potenziellen Wert bietet. Dieser Schritt kann als Strategie gesehen werden, um die Interessen der Unternehmensführung mit denen der Aktionäre in Einklang zu bringen.
- Grant of 3,298,611 stock options to officers, potentially aligning their interests with shareholders
- Options are immediately exercisable, providing instant potential value to recipients
- Potential dilution of existing shareholders' ownership if options are exercised
About Devonian
Devonian is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in
Devonian was incorporated in 2015 and is headquartered in
For more information, visit www.groupedevonian.com
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008196755/en/
Mr. Luc Grégoire
President and Chief Executive Officer
Devonian Health Group Inc.
Telephone: 1 (450) 979-2916
Courriel: investors@groupedevonian.com
Source: Devonian Health Group Inc.
FAQ
What is the exercise price and duration of the stock options granted by Devonian Health Group (DVHGF)?
How many stock options did Devonian Health Group (DVHGF) grant to its officers?
Are the stock options granted by Devonian Health Group (DVHGF) immediately exercisable?
What is Devonian Health Group's (DVHGF) focus as a company?
